Physician profile
Charles E Millwood
NPI 1265423545
$1,386.41
in general payments reported to CMS, 2019-2025
21 companies · $624 in 2025
The $624 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2022: $66.75 · 2023: $255 · 2024: $334 · 2025: $624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,212.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $166.00 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $150.79 | 2019-2025 | |
| Abbvie INC. | $146.49 | 2023-2025 | |
| Glaxosmithkline, LLC. | $122.16 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Exact Sciences Corporation | $105.16 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $98.26 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $89.30 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $80.28 | 2023-2025 | Repatha, Otezla, Otezla |
| Abbott Laboratories | $79.59 | 2024-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $73.21 | 2023-2025 | Veozah |
| Inari Medical, INC. | $57.06 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Vital Connect, INC | $55.32 | 2025 | Vitalpatch Rtm |
| Corcept Therapeutics | $30.15 | 2025 | Korlym |
| Stryker Corporation | $21.73 | 2025 | Clottriever Bold Catheter |
| Edwards Lifesciences Corporation | $21.00 | 2024 | Sapien 3 Ultra Resilia |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $19.83 | 2024 | |
| Medtronic, INC. | $19.66 | 2025 | Intellis Adaptivestim |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.67 | 2023 | |
| Daiichi Sankyo INC. | $15.36 | 2025 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.49 | 2023 | Xifaxan, Trulance |
| Phathom Pharmaceuticals, INC. | $4.90 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Millwood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.